Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.

The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), the company announced. 1 The ...

In today’s Pharma Pulse, the FDA expands a key biologic approval for pediatric patients, and new research highlights the success of pharmacist-led testing in rural communities.

On Friday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s NVS Cosentyx (secukinumab) for younger patients. The approval covers pediatric patients 12 years and older with moderate ...

Novartis has received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) to treat paediatric patients aged 12 years and above with moderate to severe hi ...

Swiss pharma giant Novartis late Friday announced today that Cosentyx (secukinumab) received US Food and Drug Administration ...

US FDA approves Novartis Cosentyx for paediatric patients aged 12+ with moderate to severe hidradenitis suppurativa: Basel Monday, March 16, 2026, 14:00 Hrs [IST] Novartis announc ...

A new weight-based secukinumab formulation provides a new option for treatment of adolescents with moderate-to-severe hidradenitis suppurativa (HS) with the FDA’s approval, according to a press ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagn ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early ...

Psoriasis symptom and quality of life improvements occur rapidly with bimekizumab and remain durable for up to three years, study shows.

Regulatory clearance positions secukinumab as the sole IL‑17A–targeting option for pediatric HS, expanding therapeutic choice beyond historically limited adolescent interventions. IL‑17A blockade is ...